We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Autonomous Biochip Leads to Rapid Diagnostic Capability

By LabMedica International staff writers
Posted on 07 Apr 2011
A major milestone in microfluidics could soon lead to standalone, self-powered chips that can diagnose diseases within minutes. More...


The novel biochip uses trenches patterned underneath microfluidic channels that are about the width of a human hair. When whole blood is dropped onto the chip's inlets, the relatively heavy red and white blood cells settle down into the trenches, separating from the clear blood plasma.

The Self-powered Integrated Microfluidic Blood Analysis System (SIMBAS) was developed by an international team, led by scientists at the University of California Berkeley (USA) and is able to process whole blood samples without the use of external tubing and extra components. The blood moves through the chip in a process called degas-driven flow, where air molecules inside the porous polymeric device are removed by placing the device in a vacuum-sealed package. When the seal is broken, the device is brought to atmospheric conditions, and air molecules are reabsorbed into the device material. This generates a pressure difference, which drives the blood fluid flow in the chip.

For the new SIMBAS biochip, the scientists took advantage of the laws of microscale physics to speed up processes that may take hours or days in a traditional laboratory. In experiments, they were able to capture more than 99% of the blood cells in the trenches and selectively separate plasma using this method. The team demonstrated the proof-of-concept of SIMBAS by placing into the chip's inlet a 5 µL sample of whole blood that contained biotin at a concentration of about one part per 40 billion. The biodetectors in the SIMBAS chip provided the readout of the biotin levels in 10 minutes and the limit of detection was 1.5 picomoles.

Luke P. Lee, PhD, the principal investigator of the study, said, "Field workers would be able to use this device to detect diseases such as human immunodeficiency virus (HIV) or tuberculosis in a matter of minutes. The fact that we reduced the complexity of the biochip and used plastic components makes it much easier to manufacture in high volume at low cost." The study was published online in March 17, 2011, in Lab on a Chip.

Related Links:
University of California



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
All-in-One Molecular System
AIO M160
New
Silver Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.